Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.53 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11206003 | 0.98 | GFER (0.56) | GFERCYP19A1MAOBMAOANPC1 | |
| SCHEMBL7146312 | 0.94 | GFER (0.52) | GFERCYP19A1MAOBMAOANPC1 | |
| SCHEMBL1338713 | 0.87 | NR3C1 (0.44) | CYP19A1MAOBTDP1TSHRTAAR1 | |
| SCHEMBL1165563 | 0.87 | GFER (0.50) | GFERCYP19A1MAOBMAOANPC1 | |
| SCHEMBL13625390 | 0.86 | GFER (0.54) | GFERCYP19A1MAOBMAOANPC1 | |
| SCHEMBL1048406 | 0.86 | TAAR1 (0.61) | MAOBTDP1ALDH1A1TSHRTAAR1 | |
| SCHEMBL11207570 | 0.85 | MAOB (0.57) | GFERCYP19A1MAOBMAOANPC1 | |
| SCHEMBL9519264 | 0.82 | GFER (0.45) | GFERCYP19A1MAOBMAOANPC1 | |
| SCHEMBL23291144 | 0.81 | TAAR1 (0.52) | GFERCYP19A1MAOBMAOAALDH1A1 | |
| SCHEMBL4459621 | 0.81 | HRH3 (0.46) | MAOBTAAR1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114763346-B | Compounds for inducing cartilage formation and application thereof | 华东师范大学 | 2025-06-10 | — | — | CN | disclosed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4065117-B1 | ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME | GLIAPHARM SA (CH) | 2024-06-19 | — | — | EP | disclosed |
| US-11925632-B2 | Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome | GLIAPHARM SA (CH) | 2024-03-12 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230102415-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME | GLIAPHARM SA (CH) | 2023-03-30 | — | — | US | disclosed |
| CN-111212627-B | Powder composition comprising a hair substantive dye | 花王株式会社 | 2023-02-17 | — | — | CN | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2004106292-A1 | HALOETHYL UREA COMPOUNDS AND THEIR USE TO ATTENUATE, INHIBIT OR PREVENT NON-CANCEROUS PATHOGENIC CELLULAR PROLIFERATION AND DISEASES ASSOCIATED THEREWITH | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106291-A1 | HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-4964876-A | Blue anthraquinone disperse dyes and mixtures of blue disperse dyes | CIBA-GEIGY CORPORATION (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0344106-A2 | Disperse blue dyes and mixtures of disperse blue dyes | CIBA-GEIGY AG (CH) | 1989-11-29 | — | — | EP | disclosed |
| US-4702906-A | SHAMPOO, HAIR DYES | SOCIETE ANONYME DITE: L'OREAL (FR) | 1987-10-27 | — | — | US | disclosed |
| US-4517174-A | Hair treatment compositions based on polycationic polymers | SOCIETE ANONYME DITE: L'OREAL (FR) | 1985-05-14 | — | — | US | disclosed |
| US-4411884-A | Cosmetic agents based on polycationic polymers, and their use in cosmetic compositions | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11925632-B2 | Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome | SLC2A1, SLC2A2, SLC2A3 | GFER 3652/4885CYP19A1 1874/4885MAOB 2136/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CYP19A1 1461/4885MAOB 629/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CYP19A1 1461/4885MAOB 629/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CYP19A1 1461/4885MAOB 629/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885CYP19A1 1461/4885MAOB 629/4885 |
| US-20230102415-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME | SLC2A1, SLC2A2, SLC2A3 | GFER 3652/4885CYP19A1 1874/4885MAOB 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.